Guangzhou Lupeng Pharmaceutical Company Ltd.

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell lymphoma has returned or not responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs t…

This study is testing whether a new drug called rocbrutinib works better than currently approved drugs for people with mantle cell lymphoma that has come back or stopped responding to prior treatment. About 394 participants will be randomly assigned to receive either rocbrutinib …

This study is testing whether an experimental drug called Rocbrutinib works better than standard therapy for adults with a specific type of aggressive lymphoma that has returned or not responded to at least two prior treatments. About 150 participants will be randomly assigned to…

This early-stage study aims to understand how two common medications—itraconazole and rifampin—affect how the body processes the drug rocbrutinib. It involves 28 healthy volunteers who will take rocbrutinib alone and then with the other drugs. The goal is to gather safety data to…